CY2007025I2 - 3-piperidinyl-1,2-benzisoxazoles - Google Patents

3-piperidinyl-1,2-benzisoxazoles

Info

Publication number
CY2007025I2
CY2007025I2 CY200700025C CY2007025C CY2007025I2 CY 2007025 I2 CY2007025 I2 CY 2007025I2 CY 200700025 C CY200700025 C CY 200700025C CY 2007025 C CY2007025 C CY 2007025C CY 2007025 I2 CY2007025 I2 CY 2007025I2
Authority
CY
Cyprus
Prior art keywords
benzisoxazoles
piperidinyl
Prior art date
Application number
CY200700025C
Other languages
English (en)
Other versions
CY2007025I1 (el
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY2007025I2 publication Critical patent/CY2007025I2/el
Publication of CY2007025I1 publication Critical patent/CY2007025I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY200700025C 1988-11-07 2007-10-15 3-piperidinyl-1,2-benzisoxazoles CY2007025I1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26785788A 1988-11-07 1988-11-07

Publications (2)

Publication Number Publication Date
CY2007025I2 true CY2007025I2 (el) 2009-11-04
CY2007025I1 CY2007025I1 (el) 2009-11-04

Family

ID=23020416

Family Applications (2)

Application Number Title Priority Date Filing Date
CY192689A CY1926A (en) 1988-11-07 1989-10-30 Novel 3-piperidinyl-1,2-benzisoxazoles
CY200700025C CY2007025I1 (el) 1988-11-07 2007-10-15 3-piperidinyl-1,2-benzisoxazoles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY192689A CY1926A (en) 1988-11-07 1989-10-30 Novel 3-piperidinyl-1,2-benzisoxazoles

Country Status (21)

Country Link
EP (1) EP0368388B1 (el)
JP (1) JP2758045B2 (el)
KR (1) KR0146053B1 (el)
AT (1) ATE122349T1 (el)
AU (1) AU614437B2 (el)
CA (1) CA2000786C (el)
CL (1) CL43432B (el)
CY (2) CY1926A (el)
DE (2) DE68922577T2 (el)
DK (1) DK169923B1 (el)
ES (1) ES2075036T3 (el)
FI (1) FI92201C (el)
HK (1) HK131696A (el)
IE (1) IE66370B1 (el)
IL (1) IL92208A0 (el)
LU (1) LU91362I2 (el)
NL (1) NL300298I2 (el)
NO (2) NO173015C (el)
NZ (1) NZ231062A (el)
PT (1) PT92206B (el)
ZA (1) ZA898436B (el)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
US5378714A (en) * 1991-11-27 1995-01-03 Novo Nordisk A/S Antipsychotic piperidine derivatives
NZ245260A (en) * 1991-11-27 1995-06-27 Novo Nordisk As Piperidine derivatives, preparation and pharmaceutical compositions thereof
ES2050069B1 (es) * 1992-07-10 1994-12-16 Vita Invest Sa Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino)etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido(1,2-a) pirimidin-4-ona.
DK60593D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
DK60793D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
DK0729357T3 (da) * 1993-11-19 2005-06-06 Janssen Pharmaceutica Nv Mikroindkapslede 1,2-benzazoler
DE69420579T2 (de) * 1993-11-23 2000-04-27 Janssen Pharmaceutica Nv 9-HYDROXY-PYRIDO [1,2-a] PYRIMIDIN-4-ON-ETHER-DERIVATE
ES2085234B1 (es) * 1994-02-24 1997-01-16 Vita Invest Sa Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2141671B1 (es) * 1997-12-26 2001-01-01 Vita Invest Sa Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
WO1999059589A1 (en) * 1998-05-18 1999-11-25 Sepracor Inc. (-)-hydroxyrisperidone compositions and methods
US6500833B1 (en) 1998-05-18 2002-12-31 Sepracor Inc. (+)-Hydroxyrisperidone compositions and methods
WO2000010572A1 (en) * 1998-08-18 2000-03-02 Sepracor Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
ES2197801B1 (es) 2002-03-05 2005-03-16 Ferrer Internacional,S.A Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
KR20040025224A (ko) * 2002-09-18 2004-03-24 주식회사 대웅 2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법
EP1560814A1 (en) 2002-11-13 2005-08-10 Synthon B.V. Process for making risperidone and intermediates therefor
EP1791839B1 (en) * 2004-09-09 2015-06-10 Janssen Pharmaceutica NV Preparation of 9-hydroxy-3-(2-hydroxyethyl)-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one and crystalls thereof
US20070197591A1 (en) 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
ES2304336T1 (es) * 2006-08-14 2008-10-16 Teva Pharmaceutical Industries Ltd. Formas cristalinas de 9-hidroxi-risperidona (paliperidona).
EP2133352A3 (en) * 2006-08-14 2010-01-13 Teva Pharmaceutical Industries Ltd. Crystal form of 9-hydroxy-risperidone (paliperidone)
EP2133351A3 (en) * 2006-08-14 2010-01-13 Teva Pharmaceutical Industries Ltd. Crystal form of 9-hydroxy-risperidone (paliperidone)
KR20090079189A (ko) * 2006-08-23 2009-07-21 테바 파마슈티컬 인더스트리즈 리미티드 Ｃｍｈｔｐ 및 이의 중간체의 합성 방법
US7820816B2 (en) 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
WO2008087557A2 (en) * 2007-01-08 2008-07-24 Actavis Group Ptc Ehf An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
RU2459824C2 (ru) * 2007-04-19 2012-08-27 Юсинь ЛИ Новые соединения для лечения психических расстройств, их получение и применение
WO2009010988A1 (en) * 2007-07-19 2009-01-22 Natco Pharma Limited An improved, industrially viable process for the preparation of high purity paliperidone
WO2009015828A1 (en) * 2007-07-27 2009-02-05 Synthon B.V. Paliperidone derivatives
WO2009045489A2 (en) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Process for the synthesis of cmhtp, a paliperidone intermediate
CA2700803A1 (en) * 2007-10-09 2009-04-16 Rajendra Narayanrao Kankan Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
WO2009074333A1 (en) * 2007-12-10 2009-06-18 Synthon B.V. Synthesis of paliperidone
EP2249649A4 (en) * 2008-02-05 2012-09-26 Watson Pharma Private Ltd IMPROVED METHOD FOR THE MANUFACTURE OF PALIPERIDONE
WO2009130710A2 (en) * 2008-04-21 2009-10-29 Glenmark Generics Limited A process for the preparation of paliperidone intermediates
US8309717B2 (en) 2008-05-29 2012-11-13 Inke, S.A. Process to prepare paliperidone and intermediates thereof
WO2010004578A2 (en) * 2008-06-16 2010-01-14 Msn Laboratories Limited Novel and improved processes for the preparation of paliperidone
WO2010003702A1 (en) * 2008-07-11 2010-01-14 Synthon B.V. Synthesis of paliperidone
WO2010003703A2 (en) * 2008-07-11 2010-01-14 Synthon B.V. Paliperidone ketone
SI22856A (sl) * 2008-07-31 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Proces za pripravo paliperidona
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
EP2199293A1 (en) 2008-12-22 2010-06-23 Chemo Ibérica, S.A. One-step process for preparing paliperidone and its oxalate salt
EP2202234A1 (en) 2008-12-24 2010-06-30 Laboratorios Lesvi, S.L. Purification of paliperidone
ATE544766T1 (de) 2009-07-13 2012-02-15 Krka Verfahren zur synthese von paliperidon
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
EP2343296A1 (en) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. A process for the purification of paliperidone
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2012035554A1 (en) * 2010-09-14 2012-03-22 Megafine Pharma (P) Ltd. An improved process for the preparation of highly pure paliperidone
EP2640391B1 (en) 2010-11-15 2015-11-11 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
CN102153552B (zh) * 2011-03-01 2012-08-22 吉林大学 两种帕潘立酮药物共晶及其制备方法
CN102206210B (zh) * 2011-04-01 2014-07-02 常州市第四制药厂有限公司 一种6-氟-3-(4-哌啶基)-1，2-苯并异噁唑盐酸盐的生产方法
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP4032889A1 (en) 2013-12-20 2022-07-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10815242B2 (en) 2015-06-19 2020-10-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11377445B2 (en) 2018-02-21 2022-07-05 Zenvision Pharma Llp Derivatives of paliperidone and process for the preparation thereof
EP3810611A4 (en) 2018-06-19 2022-03-30 Agenebio, Inc. BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS OF TREATING COGNITIVE IMPAIRMENT
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
CN116003404A (zh) * 2022-12-14 2023-04-25 杭州同舟生物技术有限公司 一种利培酮人工半抗原、人工抗原及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
JPH02191276A (ja) 1990-07-27
CA2000786C (en) 1999-01-26
CA2000786A1 (en) 1990-05-07
KR0146053B1 (ko) 1998-08-17
NL300298I2 (nl) 2008-03-03
NO2007017I1 (no) 2008-01-14
CY1926A (en) 1989-10-30
DE68922577T2 (de) 1995-09-28
FI92201C (fi) 1994-10-10
DE122007000081I1 (de) 2008-02-28
NL300298I1 (nl) 2007-12-03
NO894411D0 (no) 1989-11-06
ZA898436B (en) 1991-07-31
NO2007017I2 (no) 2010-01-25
CL43432B (es) 2005-06-03
CY2007025I1 (el) 2009-11-04
EP0368388A2 (en) 1990-05-16
FI895261A0 (fi) 1989-11-06
NO894411L (no) 1990-05-08
FI92201B (fi) 1994-06-30
DK551989D0 (da) 1989-11-06
IE66370B1 (en) 1995-12-27
IE893564L (en) 1990-05-07
JP2758045B2 (ja) 1998-05-25
DE122007000081I2 (de) 2010-01-28
DK551989A (da) 1990-05-08
NO173015C (no) 1993-10-13
EP0368388B1 (en) 1995-05-10
DK169923B1 (da) 1995-04-03
PT92206A (pt) 1990-05-31
LU91362I2 (fr) 2007-11-12
ES2075036T3 (es) 1995-10-01
EP0368388A3 (en) 1991-07-17
HK131696A (en) 1996-07-26
NZ231062A (en) 1991-09-25
PT92206B (pt) 1995-07-06
AU614437B2 (en) 1991-08-29
NO173015B (no) 1993-07-05
DE68922577D1 (de) 1995-06-14
AU4443689A (en) 1990-05-10
KR910009700A (ko) 1991-06-28
ATE122349T1 (de) 1995-05-15
IL92208A0 (en) 1990-07-26

Similar Documents

Publication Publication Date Title
CY2007025I1 (el) 3-piperidinyl-1,2-benzisoxazoles
FI893167A (fi) Moerk, neutralgrao, nickelfri glaskomposition.
FI895157A0 (fi) Laosanordning foer flyttbara anordningars, saerskilt sjukvaeddars, hjul.
NO891754L (no) Ikke-traaddannende fuktighets-herdende blandinger.
FI880189A0 (fi) Telefontrafik- eller dataoeverfoeringssystem,
FI892117A (fi) Enskiktigt, soemmat pappersmaskintyg.
FI902898A0 (fi) Lutningskompensator foer snabbgaoende fordon, saerskilt raelsfordon.
FI890176A (fi) Preventivmedel:mikrokondom.
DE3876988T2 (de) Loetgeraet.
FI894892A0 (fi) Koppling foer fluidledningar, speciellt snabbkoppling.
DK86591A (da) 14alfa,17alfa-ethanestratriener
FI893756A (fi) Slaett, keramiskt foerbindningselement.
FI896346A0 (fi) Organiska, svavelhaltiga foereningar foer anvaendning i positiva, elektrostatiska, vaetskeformiga framkallningsmedel.
FI891761A (fi) Aminosyraderivat.
FI896345A0 (fi) Bipolaert, vaetskeformigt, elektrostatiskt framkallningsmedel.
FI894455A (fi) 1,4-dihydropyridinderivat.
DE325410T1 (de) Passphotokamera.
FI892163A0 (fi) Valsanordning, saerskilt kalander.
FI895500A0 (fi) Ledning, inklusive drivanordning foer pappers- eller kartongbanor.
FI892822A0 (fi) Ljuskaensliga, negativt arbetande offsettryckplattor.
FI882802A (fi) Vaograet portenhet foer burar, saosom hoensburar.
FI883277A (fi) Transportabelt, taeckt lagerutrymme.
NO913672L (no) 14alfa,17alfa-etano-oestratriener.
FI912463A0 (fi) Synnerligen basiskt, fosfatloest, flytande tvaettmedel.
NO911826D0 (no) 14alfa,17alfa-etano-oestratriener.